These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32487617)

  • 1. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
    Nakazawa T; Murakami T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Park YS; Motoyama Y; Tsujimura T; Wakabayashi T; Nakase H
    Anticancer Res; 2020 Jun; 40(6):3231-3237. PubMed ID: 32487617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
    Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
    Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
    Kang CH; Kim Y; Lee SM; Choi SU; Park CH
    Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
    J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
    Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
    Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
    Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
    Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
    Hamblett KJ; Kozlosky CJ; Siu S; Chang WS; Liu H; Foltz IN; Trueblood ES; Meininger D; Arora T; Twomey B; Vonderfecht SL; Chen Q; Hill JS; Fanslow WC
    Mol Cancer Ther; 2015 Jul; 14(7):1614-24. PubMed ID: 25931519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H; You Y; Shen Z; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
    Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
    Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
    Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
    Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Front Immunol; 2018; 9():824. PubMed ID: 29740437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.